132 related articles for article (PubMed ID: 36070558)
1. Cost effectiveness of treatment strategies for high risk prostate cancer.
Kowalchuk RO; Kim H; Harmsen WS; Jeans EB; Morris LK; Mullikin TC; Miller RC; Wong WW; Vargas CE; Trifiletti DM; Phillips RM; Choo CR; Davis BJ; Beriwal S; Tendulkar RD; Stish BJ; Breen WG; Waddle MR
Cancer; 2022 Nov; 128(21):3815-3823. PubMed ID: 36070558
[TBL] [Abstract][Full Text] [Related]
2. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence.
Weng X; Zhong L; Xiang P; Li Y; Paciorek A; Dong L; Broering J; Carroll PR; Sanda M; Wilson L
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13740. PubMed ID: 36239065
[TBL] [Abstract][Full Text] [Related]
4. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
5. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
[TBL] [Abstract][Full Text] [Related]
7. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
8. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
9. A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.
Fischer-Valuck BW; Gay HA; Patel S; Baumann BC; Michalski JM
Front Oncol; 2019; 9():1378. PubMed ID: 31921640
[TBL] [Abstract][Full Text] [Related]
10. Low-dose rate brachytherapy for men with localized prostate cancer.
Peinemann F; Grouven U; Hemkens LG; Bartel C; Borchers H; Pinkawa M; Heidenreich A; Sauerland S
Cochrane Database Syst Rev; 2011 Jul; (7):CD008871. PubMed ID: 21735436
[TBL] [Abstract][Full Text] [Related]
11. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
[TBL] [Abstract][Full Text] [Related]
12. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of 3D image-guided brachytherapy compared with 2D brachytherapy in the treatment of locally advanced cervical cancer.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Brachytherapy; 2015; 14(1):29-36. PubMed ID: 25443528
[TBL] [Abstract][Full Text] [Related]
14. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis.
Singh AM; Gagnon G; Collins B; Niroomand-Rad A; McRae D; Zhang Y; Regan J; Lynch J; Dritschilo A
Prostate; 2005 Jan; 62(1):54-60. PubMed ID: 15389809
[TBL] [Abstract][Full Text] [Related]
15. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
16. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
Morris WJ; Pickles T; Keyes M
Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
[TBL] [Abstract][Full Text] [Related]
17. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
[TBL] [Abstract][Full Text] [Related]
19. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Morris WJ; Hamm J; Duncan G
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):581-589. PubMed ID: 28581398
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
